$MNKD OK, so we all know that the effects are compounded here. So, they are falling short again on expected Afrezza revenue, which means that they will fall short on their debt covenant obligations, which means available cash to borrow may be restricted, which also means possible interest rate increase on existing loan, which means, at face value, they wont have cash to 2021, which means more dilution, which means increase in OS, which means further decline, below $1, which means possible second R/S in 2020. If we dont get a second UTHR molecule or another big cash deal by EOY, I dont see how this goes well for SH. Just my 2 cents.
  • 6
  • 7